Cinnagen
Iran - TehranBiotechnology
Focus: Cinnagen is an Iranian biotechnology company specializing in biosimilars, generics, and molecular biology products across infectious diseases, oncology, neurology, and metabolic disorders. The company operates primarily within the Iranian pharmaceutical market with a diversified pipeline of late-stage development programs.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Cinnagen
AI assessmentNot HiringNo open roles listed right now. Follow Cinnagen to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
15 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
CinnaTropin®
Stable
Growth
Proprietary recombinant growth hormone program in Phase 3 development targeting endocrine disorders.
CinnaPoietin®
Help build intelligence for Cinnagen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.